Reversal of adriamycin resistance by verapamil in human ovarian cancer.

The effectiveness of adriamycin in the treatment of ovarian cancer and other human tumors has been limited by the development of drug resistance. Verapamil, a calcium channel blocking agent, completely reversed adriamycin resistance in human ovarian cancer cells with moderate (three- to sixfold) degrees of resistance and partially reversed resistance in highly (150-fold) resistant cells. The potentiating effect of verapamil was due to inhibition of adriamycin efflux in the resistant cells. These results have led to a clinical trial of adriamycin and verapamil in refractory ovarian cancer patients.

[1]  J. Whang‐Peng,et al.  Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. , 1983, Cancer research.

[2]  J. Jenkins,et al.  Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. , 1983, Cancer research.

[3]  T. Tsuruo,et al.  Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. , 1983, Cancer research.

[4]  J. Lautenberger,et al.  Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells , 1982, Nature.

[5]  M. Dalmark,et al.  A Fickian diffusion transport process with features of transport catalysis. Doxorubicin transport in human red blood cells , 1981, The Journal of general physiology.

[6]  R. Ozols,et al.  The anthracycline antineoplastic drugs. , 1981, The New England journal of medicine.

[7]  C. Griffiths,et al.  Combination chemotherapy with adriamycin‐cyclophosphamide for advanced ovarian carcinoma , 1980, Cancer.

[8]  J. Willson,et al.  Cloning of Human Ovarian Cancer Cells in Soft Agar from Malignant Effusions and Peritoneal Washings , 1980 .

[9]  M. Inaba,et al.  Enhanced efflux of actinomycin D, vincristine, and vinblastine in adriamycin-resistant subline of P388 leukemia. , 1979, Cancer letters.

[10]  R. Johnson,et al.  Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. , 1979, Cancer research.

[11]  R. Johnson,et al.  Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukemia. , 1978, Biochemical pharmacology.